Patients’ preferences for antiretroviral therapy service provision: a systematic review

Yihalem Abebe Belay1,2*, Mezgebu Yitayal2, Asmamaw Atnafu2 and Fitalew Agimass Taye3

Abstract

Background: Achieving global targets of adherence to treatment, retention in care, and treatment success remains a challenge. Health system investment to make antiretroviral therapy services more responsive to patients’ needs and values could address these impediments. Appropriate resource allocation to implement differentiated HIV treatment services demands research evidence. This study aimed to provide an overview of the patients’ preferences for antiretroviral therapy service delivery features.

Methods: Electronic databases (PubMed, Web of Science, Embase, and CINAHL) and search engines (Google and Google Scholar) were searched. This review has followed a convergent segregated approach to synthesis and integration. Data from the included studies were systematically extracted, tabulated, and summarised in a narrative review. Studies that analysed preferences for antiretroviral therapy regardless of the method used and published in the English language in any year across the world and HIV positive clients who were 15 years and above on 4th February 2021 were included for this review. The quality of the included studies was assessed using the mixed methods appraisal tool. A thematic synthesis of the data from the findings section of the main body of the qualitative study was undertaken. ATLAS.ti software version 7 was used for qualitative synthesis.

Results: From the 1054 retrieved studies, only 23 studies (16 quantitative, three qualitative, and four mixed-methods) fulfilled the inclusion criteria. The median number of attributes used in all included quantitative studies was 6 (Inter Quartile Range 3). In this review, no study has fulfilled the respective criteria in the methodological quality assessment. In the quantitative synthesis, the majority of participants more valued the outcome, whereas, in the qualitative synthesis, participants preferred more the structure aspect of antiretroviral therapy service. The thematic analysis produced 17 themes, of which ten themes were related to structure, three to process, and four to outcome dimension of Donabedian’s quality of care model. The findings from individual quantitative and qualitative syntheses complement each other.

Conclusions: In this review, participants’ value for antiretroviral therapy service characteristics varied across included studies. Priorities and values of people living with HIV should be incorporated in the policy, practice, research, and development efforts to improve the quality of antiretroviral therapy service hence avoid poor patient outcomes.

Keywords: Preferences, Antiretroviral therapy, Mixed-methods, Systematic review
Background
Human Immunodeficiency Virus (HIV) infection continues to be a major public health issue throughout the world. Since the start of the pandemic, 75.7 million people have become infected, and 32.7 million people have died from AIDS-related illnesses. Globally by the end of 2019, 38 million people were living with HIV, 1.7 million people were newly infected, and 690,000 people died from AIDS-related illnesses [1, 2]. Over two-thirds (25.7 million) of all people living with HIV reside in Africa [2].

The Sustainable Development Goal (SDG) 3 includes the promise made by the Member States to achieve the end of AIDS by 2030 [3]. To address this issue, the UNAIDS put the target to have 90% of all people living with HIV (PLHIV) will know their HIV status, 90% of those diagnosed with HIV infection will receive a sustained combination of antiretroviral therapy (ART), and 90% of all people receiving ART will have suppressed viral load by 2020. A subsequent 95-95-95 goal is set for 2030 [4]. Moreover, the World Health Organization (WHO) recommends ART for all people diagnosed with HIV (test and treat approach) [5]. Despite such global efforts, ensuring adherence to HIV treatment, retention in care, and treatment success are challenges to low and middle-income countries (LMICs), which require commitment from the patient and the healthcare team and a productive patient-provider relationship [2].

As the availability of ART for the treatment of HIV/AIDS has increased in resource-limited settings, there has been a move to develop and implement alternative treatment delivery models (also referred to as “differentiated models of service delivery” or DSD) in high HIV prevalence countries to meet the global targets for HIV treatment while maintaining the quality of care [6]. Differentiated ART delivery is a component of DSD. It aims to improve retention and viral suppression by optimizing models of drug and care delivery. Differentiated ART delivery focuses specifically on clients who are on treatment [7].

Differentiated models of ART service delivery typically differ across one or more of the service characteristics (provider, location, time, frequency, and intensity of care) and aim to provide a more patient-centered service [8, 9]. Four DSD models that focus on stable ART clients are recently identified [10, 11]. They include (1) healthcare worker (HCW) managed groups, (2) facility-based individual models, (3) client managed groups, and (4) out-of-facility individual models. In HCW managed groups, clients receive their ART refills in a group either from a health professional or a lay healthcare staff member. In these models, clients meet in and/or outside of the health care facilities. In facility-based individual models, clients bypass any clinical staff or adherence support and proceed directly to receive their medication. Appointment spacing and the “fast-track” ART refill model are an example of these models. In client-managed group models, clients receive their ART refills in a group in which clients meet outside of health care facilities and manage and run the refills themselves. For out-of-facility individual models, ART refills and, in some cases, clinical consultations are provided to individuals outside of health care facilities; for example, community pharmacies, outreach models, and home delivery [7].

WHO has defined stable individuals as “those who have received ART for at least 1 year and have no adverse drug reactions that require regular monitoring, have no current illnesses or pregnancy, have not been currently breastfeeding, have a good understanding of lifelong adherence and evidence of treatment success (i.e., two consecutive viral load measurements below 1000 copies/ml). However, in the absence of viral load monitoring and rising CD4 cell counts or CD4 counts > 200 cells/mm³, an objective adherence measure can be used to indicate treatment success” [5].

Implementation and strategy prioritization of HIV programs have been difficult in most resource-limited settings [12]. Research and development are required in this regard to bring more innovative ART delivery models. Through the understanding of the aspects of antiretroviral therapy that are of particular importance to PLHIV, it may be possible to develop new models of care that maintain these high levels of adherence, engagement with care, and treatment success. Nowadays, patient preferences studies are increasingly used to inform clinical and policy decision-making in health care in the context of resource constraints [13]. Several quantitative and qualitative studies assessing patients’ preferences for ART service have been published, although a little attempt has been made to synthesize the research findings. Previous reviews lacked particular focus and in-depth investigation of ART service provision. Most of the systematic reviews were conducted on the general HIV care aspects (prevention, counseling and testing, service delivery, and ART) [14, 15], included only discrete choice experiment-based studies on HIV treatment service ignoring other designs [16], and focused on HIV care in high-income countries which are not highly affected by the HIV pandemic [14].

This study was a mixed systematic review to contribute to a better and comprehensive understanding of patients’ preferences for ART service provision. It was designed to elaborate on preferences of HIV-positive clients aged 15 years and above, with the goal of aiding policymakers, program managers, and practitioners in Ethiopia and other settings as they expand ART services.
Methods

Protocol registration
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline [17] was used to report the result of this mixed-method systematic review. Protocol for this review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database on ID no: CRD42020212064.

Databases and search strategy
The literature search was undertaken from inception to 4th February 2021 using PubMed, Web of Science, Embase, and CINAHL databases. In addition, articles were selected using manual search via Google and Google Scholar search engines by combining the search terms used for databases accessed for primary data sources. The SPIDER question framework was employed, and searches used free text and MeSH terms relating to the following: (i) sample (patients); (ii) the phenomena of interest (antiretroviral therapy, antiretroviral treatment, human immunodeficiency virus therapy, HIV treatment, HIV medication, HIV/AIDS therapy, HIV/AIDS treatment, differentiated antiretroviral therapy); (iii) evaluation (preference, patient preference, stated preference, stated choice); and (iv) research type (qualitative, mixed-methods, and quantitative such as conjoint analysis, discrete choice experiment, ranking study, swing weighting study, analytical hierarchy process, best–worst scaling, adaptive conjoint analysis) for all available studies. Besides, the reference lists of included articles were searched manually. The search string was developed using “AND” and “OR” Boolean Operators. The complete search strategy based on keywords is available in Additional file 1.

Study eligibility and selection
The eligible studies were selected based on the following criteria: (1) analysis of preferences for ART regardless of the method used, (2) being written in English, and (3) sampling of HIV-positive individuals aged 15 years and above. Studies conducted on HIV services other than ART (prevention, counseling and testing, and service delivery); review articles and studies conducted among children, adolescents, pregnant and breastfeeding women and key populations (people who inject drugs, men having sex with men, transgender persons, sex workers, and prisoners) due to special criteria for defining clinically stable clients and key considerations for social and legal issues in accessing ART services were excluded from this review.

All retrieved studies were exported to Endnote version 9 (Thomson Reuters, London) reference manager, and duplicates were carefully removed. Two investigators (YAB and FAT) independently screened thorough review from the title, abstract, and full text of each study. Any disagreements that arose between the reviewers were resolved through discussion.

Assessment of methodological quality
Two independent reviewers (YAB and MY) assessed the quality of the studies. The Mixed Methods Appraisal Tool (MMAT) [18] was used to evaluate the quality of included studies. This tool includes specific criteria for mixed methods studies, as well as for qualitative and quantitative studies. The tool discourages the use of a scoring system and instead advises to put a detailed presentation of the ratings to provide a better explanation of the quality of the included studies. Any disagreements that arose between the reviewers were resolved through discussion.

Due to the complexities associated with recommendations being derived from both quantitative and qualitative evidence, an assessment of the certainty of the evidence using either the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) or ConQual approach is currently not recommended for JBI Mixed methods research following the segregated approach and not yet assessed in this review [19].

Data extraction
The data from primary level studies conducted using qualitative, quantitative, and mixed methods were extracted using JBI data extraction tools in the form of customized Microsoft Excel [20]. Two independent reviewers (YAB and AA) extracted the data and cross-checked it to ensure consistency. Discrepancies were solved by discussion and repeating the procedure. The reviewer (YAB) contacted the corresponding author(s) for further information whenever pertinent data was missed from the included studies. Descriptive data were sorted from the studies focused on authors, study aim, year of publication, country, study region, study type, sample size, method of sample recruitment, method of data collection, and data analysis (Additional file 2).

For quantitative studies (and the quantitative component of mixed methods studies), the extracted data included specific details about the method of preference elicitation, attributes (levels), number of attributes, dimension of attributes, and importance of attributes. For qualitative studies (and the qualitative component of mixed methods studies), extracted data included specific details about the themes, key concepts, and relevant quotes appropriate to the review question.
Data synthesis and integration
This review followed a convergent segregated approach to synthesis and integration, according to the JBI methodology for mixed-methods systematic review [19]. It involved a separate quantitative and qualitative synthesis followed by integration of the resultant quantitative and qualitative evidence. The quantitative data were examined and found to be inappropriate for a meta-analysis due to the occurrence of high heterogeneity in the study designs and results, i.e., different methods to assess preferences, differences in the choice and the definition of attributes and levels, and different ways of reporting results. A thematic synthesis of the qualitative studies was undertaken following the recommendation of Thomas and Harden [21]. ATLAS.ti software version 7 was used for qualitative data synthesis. Both quantitative and qualitative findings were presented in narrative form, including tables and figures. A narrative summary was used for the final integration of the results of the quantitative and qualitative evidence.

In this systematic review, we considered a mixed-methods type of research as studies reported using either one or more qualitative data collection methods (in-depth interviews, focus group discussions, etc.) and one of the stated preference survey methods in the same published study with clear and sufficient reported methods and findings.

In this review, we divided the identified attributes into three dimensions: structure, process, and outcome. These dimensions were based on Donabedian’s model for health care quality and were appropriate to group the wide range of ART service attributes and to have a closer look at what dimensions of ART were most important for the respondents while choosing ART service delivery. The dimension “structure” refers to objective parameters such as material resources, personnel resources and organizational structure. The “Process” dimension includes all activities taking place while giving and receiving ART. The dimension “outcome” denotes the effect of ART service on the health status of patients [22]. Similarly, the impact of each attribute on patient preference regarding ART in each included study was shown by ranking and/or rating the preference (utility) values; and relative importance score, mean, or odds ratio was used depending on the reported data. The relative importance, expressed as a percentage of each of the attributes in influencing treatment decisions, was calculated for each participant by dividing the range of each attribute (utility of highest level minus utility of lowest level) by the sum of the ranges of all attributes, and multiplying it by 100 [23–25]. If a study reported the utility coefficients in a continuous scale of measurement, then the coefficients for discrete levels of each attribute were calculated in reference to a baseline category with the lowest utility value in the same attribute. In the case of the odds ratio reported in a study, the relative impact of each attribute was computed by dividing the highest odds ratio value by the lowest odds ratio value [16]. However, for studies other than discrete choice experiments (rating, ranking, or best–worst scaling studies) included in this review, the reported rankings in the form of mean, relative importance score, or graphical presentation were directly taken.

Results
Study inclusion
The search strategy resulted in 1004 records through (PubMed = 456, Web of Science = 186, Embase = 311 and CINAHL = 51) databases. In addition, 50 studies were accessed manually using Google and Google Scholar search engines. From these, 422 duplicated records were excluded, and from articles screened using their titles and abstracts, 598 were excluded. Therefore, 34 articles were assessed for eligibility. From these, 11 articles were excluded: three were abstracts without full text [26–28], three were review articles focusing on general HIV services [14–16], one study assessed HIV infected pregnant women [29], one study was repeated publication [30], one primary study focused on general HIV service [31], one study assessed General practitioner or HIV clinic appointment [32], and one study assessed medical and psychosocial support [33]. Finally, 23 studies were included in the review. Figure 1 has shown the study selection process.

Methodological quality of included studies
The methodological quality of included studies varied. All studies presented clear research questions and collected data to address the questions. All the qualitative studies used adequate data collection methods to address the research question, reported the interpretation of results sufficiently substantiated by data, reported the findings adequately derived from the data (for example, the quotes provided to justify the themes were adequate), and provided coherence between qualitative data sources, collection, analysis, and interpretation. About one-fifth of the quantitative studies had samples that accurately represented the target population. Nearly two-thirds of studies had pre-tested questionnaires before data collection. One-fifth of the quantitative studies had reported a non-response rate indicating a low risk of non-response bias. Most quantitative studies used appropriate statistical analysis to answer the research questions. All mixed methods studies reported an adequate rationale for using a mixed-methods design to address the research question. None of the mixed methods had the different components of the study adhere to the quality criteria of each
tradition of the methods involved. The integration of both qualitative and quantitative evidence was effective, and results were well interpreted, and there was no divergence of the qualitative and quantitative findings. Overall, no study fulfilled the respective quality criteria. However, in this systematic review, no study was excluded owing to its methodological quality since we were interested in synthesizing all features of ART provision that have been identified as being relevant to PLHIV. The quality assessment matrix is presented in Additional file 3.

Characteristics of included studies

Our data comprised of seven studies from the African region [34–40], 10 in the Americas [23, 41–49], five in Europe [50–54], and one in both the Americas and Europe (USA and Germany) [55]. Sixteen studies were quantitative [23, 34, 36, 38, 40, 41, 43, 44, 46–48, 51–55] and three were qualitative [35, 39, 42]. Four articles reported both qualitative and quantitative findings [37, 45, 49, 50]. The studies were published between 2002 and 2020. All studies included adult PLHIV in their samples. Twelve studies (eight quantitative and four quantitative parts of mixed methods) recruited the participants using a non-probability sampling technique. Half of the non-qualitative studies were interviewer-administered through paper or tablets. The majority of quantitative and (quantitative part of mixed methods) studies applied mixed logit analytic method whereas thematic analysis was applied in nearly half of qualitative and (qualitative part of mixed methods) studies (Table 1).

Quantitative synthesis

Method of preference elicitation

Patients’ preferences were elicited with DCE/conjoint analysis method in 12 studies [23, 34, 36–38, 40, 43, 46, 48, 50, 52, 54]; rating exercise [47, 51], ranking exercise [49] and adaptive conjoint analysis [41, 55] in two studies each; and pair-wise comparison [45], and Best–Worst Scaling 1 [44] in one study each (Table 2).

Attributes and dimensions

The review showed that the number of attributes ranged from 3 to 26 per study. The median number of attributes used in all included quantitative studies was 6 (Inter Quartile Range 3). Regarding the attributes identified and selected in the included studies, they were clustered into the structure, process, and outcome dimensions of antiretroviral therapy service provision [22]. Overall, the studies used 11 different structure attributes, two process attributes, and ten outcome attributes (Table 3). When summed up, 149 attributes (95 outcome attributes, 47 structure attributes, and seven process attributes) were identified in the included studies (see Table 4). The attributes “Side effect” (n = 13) and “Efficacy” (n = 12) were the
| Author       | Aim of study                                                                 | Publication year | Country     | Type of study | Sample                                                                 | Sampling method | Method of data collection       | Method of data analysis     |
|--------------|------------------------------------------------------------------------------|------------------|-------------|---------------|------------------------------------------------------------------------|-----------------|--------------------------------|----------------------------|
| Zanolini [40]| To quantify preferences for a number of potential clinic improvements to enhance retention | 2018             | Zambia      | Quantitative  | 385 adult HIV patients who were lost to follow-up                      | Random          | Tablet-based interview          | Mixed logit                 |
| Opuni [36]   | To measure preferences for characteristics of hypothetical ART clinics       | 2010             | South Africa| Quantitative  | 510 adult HIV-infected patients                                       | Not stated clearly| Interview                      | Random intercept logit model |
| Tanle [39]   | To examine the preferences of PLHIVs concerning ART services                 | 2017             | Ghana       | Qualitative    | 145 FGDs and 171 IDIs PLWHIV                                          | Volunteer       | FGD and IDI                     | Thematic analysis           |
| Rabkin [37]  | To explore treatment preferences of PLHIV                                    | 2020             | Zimbabwe    | Mixed methods   | 35 KIlS, 8 FGDs and 500 survey participants                            | Purposive sampling of KIlS and convenience sample of FGD and survey participants | KIl and FGD, and tablet-based interview | Framework analysis and Fixed effects logit model |
| Strauss [38] | To assess patient preferences for differentiated HIV treatment delivery model characteristics | 2020             | Zimbabwe    | Quantitative   | 500 stable adults on ART                                              | Purposive       | Tablet-based interview          | Mixed-effects logit         |
| Muiruri [35] | To understand preferences for ART packaging                                 | 2020             | Tanzania    | Qualitative    | 16 adult PLWHIV receiving HIV care                                    | Purposive       | In-depth interview              | Thematic analysis           |
| Eshun [34]   | To determine what DSD features stable patients on ART most prefer            | 2019             | Zambia      | Quantitative   | 486 adult HIV patients on ART                                         | Random          | Tablet-based interview          | Mixed logit                 |
| Mühlbacher [54] | To explore patient preferences regarding treatment of HIV/ AIDS            | 2013             | Germany     | Quantitative   | 218 HIV patients                                                     | Not stated      | Self-administered online or offline | Random effect logit model |
| Lloyd [52]   | To elicit patient and physician preferences for HIV treatment options       | 2013             | United Kingdom| Quantitative  | 200 HIV patients                                                     | Not stated      | Online self-administered       | Conditional logit model     |
| Author       | Aim of study                                                                 | Publication year | Country            | Type of study | Sample                        | Sampling method                      | Method of data collection                      | Method of data analysis                  |
|--------------|------------------------------------------------------------------------------|------------------|--------------------|---------------|-------------------------------|--------------------------------------|-------------------------------------------|------------------------------------------|
| Fuster [51]  | To determine HIV patients’ ratings of the characteristics of combined antiretroviral treatment | 2015             | Spain              | Quantitative  | 602 HIV patients attending external consultations in HIV clinics | Casual or incidental non-probabilistic sampling | Self-administered questionnaire | Exploratory factor analysis, cluster analysis, and Student’s t-test for independent samples |
| Brégigeon [50] | To elicit patient preferences regarding the principal characteristics of ARV therapies and to explore satisfaction of PLWH with their current ARV therapies | 2017             | France             | Mixed methods  | Adult patients taking ART: 101 PLWH took part in the quantitative and 31 in the qualitative part | Consecutive                          | Quantitative interview and IDI            | Mixed logit and thematic analysis         |
| Moyle[53]    | To assess the needs of persons living with HIV regarding ART and to investigate the obstacles currently experienced by European patients when taking or commencing therapy | 2003             | France, Germany, Italy, Spain, and the UK | Quantitative  | 504 people with HIV | Posters at HIV specialist care centers and through advertisements in patient-oriented magazines, newspapers, and charities | Interview                               | Descriptive                              |
| Beusterien [41] | To quantify the relative importance of new generation, third-agent HIV drug attributes based on their severity and levels of risk | 2005             | USA                | Quantitative  | 42 adult HIV-positive individuals | Newspaper advertisement               | Computer-administered                  | Ordinary least squares regression         |
| Miller [45]  | To assess patients preferences for different aspects of antiretroviral regimens | 2002             | USA                | Mixed methods  | 47 FGD among adult HIV patients on ART and 62 patients for quantitative interview | Consecutive                          | FGD and quantitative interview           | Graded pair-preferences method for the quantitative part but not stated for the qualitative part |
| Eaton [42]   | To understand patient preferences for contemporary antiretroviral therapy    | 2017             | USA                | Qualitative   | 28 PLWH > = 19 years old who initiated ART on January 1, 2006 | Using flyers, staff referrals, and electronic screens | Nominal group technique                 | Multi-voting technique                   |
| Author       | Aim of study                                                                 | Publication year | Country  | Type of study     | Sample                                      | Sampling method                                                                 | Method of data collection       | Method of data analysis                     |
|--------------|-------------------------------------------------------------------------------|------------------|----------|-------------------|---------------------------------------------|--------------------------------------------------------------------------------|---------------------------------|---------------------------------------------|
| Yelverton [49] | To identify ART characteristics that are important to patients and understand considerations in ART selection from both patient and provider perspectives | 2018             | USA      | Mixed methods     | Adult HIV infected individuals on ART; 16 IDIs and 26 for ranking tasks | Patients were recruited by their attending physician, word of mouth, and clinic advertisements | In-depth interviews (IDIs) with HIV patients for the qualitative part and Ranking tasks | Content analysis (qualitative) and count analysis (quantitative) |
| Sherer [47]  | To evaluate the importance of ART attributes                                   | 2005             | USA      | Quantitative      | 387 adult HIV-positive patients who were currently receiving or had previously received ART | Convenience sampling using flyers                                           | Interview                       | Paired sample t-tests                       |
| Ostermann [46] | To quantify patients’ preferences for key characteristics of modern ART        | 2020             | USA      | Quantitative      | 263 adult PLWH                                 | Flyers and invitation cards, referrals from providers, patients, and members of a community advisory board, and recruitment of patients after clinic appointments | Interview                       | Mixed logit                                  |
| Sijstermans [48] | To assess patients’ preferences for HIV treatment in an urban Colombian population | 2020             | Colombia | Quantitative      | 224 HIV patients                               | All patients with HIV in a single City                                    | Self-administered questionnaire | Mixed multinomial logit                      |
| Goossens [23] | To elicit patients’ preferences for HIV treatment in the rural population of Colombia | 2020             | Colombia | Quantitative      | 148 HIV patients                               | All patients with HIV in a single City                                    | Self-administered               | Mixed logit model                           |
| Hendriks [44] | To elicit patients’ preferences for HIV/AIDS treatment characteristics in Colombia | 2018             | Colombia | Quantitative      | 283 People living with HIV/AIDS                  | Not clearly stated                                                        | Self-administered questionaire | Hierarchical Bayes method                   |
two outcome attributes commonly used in the included studies. The most commonly used structure attribute was “Dosing and administration”. Other attributes of this dimension that were frequently cited were “Waiting time at the clinic” (n = 5), “Cost of visit” (n = 5), and “Frequency of visit” (n = 4). “Staff attitude” was a commonly used process attribute (n = 4).

Table 2  Methods of preference elicitation

| Method of preference elicitation | Number (%) |
|---------------------------------|------------|
| Discrete choice experiment/conjoint analysis | 12 (60%) |
| Rating exercise | 2 (10%) |
| Ranking exercise | 2 (10%) |
| Adaptive conjoint analysis | 2 (10%) |
| Pair-wise comparison | 1 (5%) |
| Best Worst Scaling | 1 (5%) |

Table 3  Attributes and dimensions of antiretroviral therapy

| Attributes | Number of studies using attribute |
|------------|----------------------------------|
| Structure attributes (n = 11) | |
| Dosing and administration | 8 |
| Waiting time at the clinic | 5 |
| Cost of visit | 5 |
| Frequency of visit | 4 |
| Distance | 3 |
| Operation time | 3 |
| Location of service delivery | 3 |
| Characteristics related to simplifications | 2 |
| HIV clinic branding | 1 |
| Buddy system | 1 |
| Available clinical evidence or information | 1 |
| Process attributes(n = 2) | |
| Staff attitude | 4 |
| Participants/others seen at the same visit | 3 |
| Outcome attributes(n = 10) | |
| Side effect | 13 |
| Efficacy | 12 |
| Long term health effect | 6 |
| Regimen convenience | 5 |
| Long duration of drug | 2 |
| Interactions | 1 |
| Therapy-free intervals possible | 1 |
| The drug allows further therapy options | 1 |
| It can also be used in case of comorbidities | 1 |
| Pregnancy allowed | 1 |
Preferences for ART and relative attribute importance
Four studies were excluded from attribute importance analysis due to a study reported mean preference rankings for regimen A and regimen B separately [45], there was a mean percent importance difference between Treatment-Naive and Treatment-Experienced participants [55], attributes were on different underlying scales [52], and the total number of ranks varied due to ties and exclusion of no important characteristics [49] (Table 4). The included 20 quantitative studies were based on a wide range of attributes related to ART service. There was heterogeneity in the results of preference estimates as the attributes were diverse across the included studies. Eight studies evaluated the dosing and administration of drugs. Overall, PLHIV needed a lower pill burden, smaller pill size, and lower frequency of drug-taking [44–47, 49, 53, 54]. The preference value ranking attached to the attribute “Clinic waiting time” varied, ranging from 1 to 6 among five studies [34, 36–38, 40]. In general, participants wanted a shorter duration of waiting time till the upcoming appointment. The participants choice rank for the attribute “Cost of visit” was heterogeneous across the five studies [23, 36–38, 48]. Participants did not want to pay for ART services. The evidence from 4 studies found that participants preferred less frequent clinic visits [34, 37, 38, 40]. Good provider attitude was highly valued by participants ranked either first in two studies [37, 38] and second in another two studies [36, 40]. The better efficacy of antiretrovirals (ARVs) was highly valued by participants, as shown by the 12 studies [23, 41, 43–45, 47, 48, 50–54]. Participants of the included studies also valued reduced or no side effects of ARVs as reported in the 13 included studies [23, 41, 43–49, 51–53, 55]. Similarly, participants had more value on low or no long-term health problems following taking medications as reported in the included six studies [43, 44, 46, 49, 52, 54] (Table 4).

Qualitative synthesis
Qualitative evidence about patient preferences for ART service provision was reported in seven studies [35, 37, 39, 42, 45, 49, 50]. Data from qualitative studies were also organized into the structure, process, and outcome dimensions of the quality of care [22]. The thematic analysis produced ten themes under structure, three themes under process, and four themes under outcome dimension. However, the themes of inconvenience and novel ART delivery methods were categorized under both the structure and outcome dimensions. Table 5 summarizes initial concepts, emergent themes, final themes, supporting quotes, and dimensions of the final themes.

Structure aspect of antiretroviral therapy
Source of information on ART One study highlighted the source of information on ART could affect the preferences of PLHIV regarding the ART service provision [39].

Preferred place for ART service Two studies evaluated a preferred place for ART service. Participants preferred health facility-based service to home-based ART service since this model gives the patients the opportunities to have hospital education and preparation before initiating a drug, meet and interact with colleagues, discuss with providers, have access to psychosocial support, and avoid stigma and discrimination [37, 39].

Preferred person to deliver ART service One study asked participants whom they preferred to deliver ART service. Participants’ choice of the service provider (health worker, trained PLHIV or foreigner) varied depending on the issues related to knowledge on ART, training, experience, encouraging patients to feel free to go to health facilities and avoiding a feeling of shyness, and maintaining confidentiality and interaction with patients [39].

Cost of ART medications Three studies evaluated the costs related to ART services [39, 42, 49]. Most patients preferred either a reduced or free drug cost. Some patients, however, were willing to pay whatever amount required as the drug is available.

Time spent at ART clinics and times (hours and days) of operation Two studies evaluated the waiting and clinic operation times at health facilities [37, 39]. Participants preferred shorter waiting times to obtain ART and flexible clinic hours.

Visit frequency One study asked participants about their preferred frequency of visits for ART pick-ups. Participants chose less frequent appointments (once or twice a year visit with larger supplies of ART dispensed at each visit) [37].

Pill burden and pill size One study evaluated the trade-off participants have on the pill size and pill burden. Some participants had a concern about swallowing big pills and most preferred single tablets. Some of them were willing to accept a higher pill burden in exchange for reduced side or long-term effects [49].

Drug administration Three studies examined the preference for drug administration [35, 42, 49]. Some participants preferred the drug in the form of a liquid, capsule, or injection to avoid swallowing of pills, lower the intake frequency and/or avoid a feeling of burden due to daily drug-taking and unpleasant drug taste.

ART packaging One study asked participants regarding their preference and recommendations for ART packaging [35, 37]. Participants identified three attributes of ART packaging that increased anticipated HIV stigma and prompted self-repackaging, including visual
| Authors       | Attributes (levels)                                                                 | Dimension of attribute | Attribute importance | Most important attribute                                      |
|--------------|-----------------------------------------------------------------------------------|------------------------|----------------------|--------------------------------------------------------------|
| Zanolini     | Waiting time at the clinic (1, 3, or 5 h)                                         | Structure              | 4 (5.20%)            | ART supply is given at each refill                           |
|              | Distance from residence to the clinic (5, 10, or 20 km)                           | Structure              | 3 (6.20%)            |                                                              |
|              | ART supply is given at each refill (1, 3, or 5 months)                            | Structure              | 1 (52.70%)           |                                                              |
|              | Hours of operation (morning only, morning and afternoon, or morning and Saturday) | Structure              | 5 (3.10%)            |                                                              |
|              | Staff attitude (rude or nice)                                                      | Process                | 2 (32.80%)           |                                                              |
| Beusteriena  | Moderate to severe diarrhea (involving five or more loose stools per day) (1%, 8% or 16% chance) | Outcome                | 5 (7.10%)            | Chance of developing resistance                             |
|              | Moderate to severe nausea (5%, 10% or 14% chance)                                  | Outcome                | 6 (6.90%)            |                                                              |
|              | Moderate to severe vomiting (2%, 5% or 7% chance)                                  | Outcome                | 10 (4.70%)           |                                                              |
|              | Moderate to severe rash (1%, 5% or 10% chance)                                     | Outcome                | 9 (5.00%)            |                                                              |
|              | Moderate to severe jaundice (<1% or 6% chance)                                     | Outcome                | 10 (4.70%)           |                                                              |
|              | Moderate to severe dizziness (<1%, 3% or 6% chance)                                | Outcome                | 7 (5.80%)            |                                                              |
|              | Moderate to severe depression (<1% or 5% chance)                                   | Outcome                | 8 (5.50%)            |                                                              |
|              | Moderate to severe sleep problems (<1%, 10% or 25% chance)                         | Outcome                | 3 (8.60%)            |                                                              |
|              | Virologic failure (7%, 15% or 21% chance)                                          | Outcome                | 4 (8.20%)            |                                                              |
|              | Increasing cholesterol (very low, moderate, or high chance)                        | Outcome                | 5 (7.10%)            |                                                              |
|              | Chance of developing resistance (very low, low, moderate, high, or very high chance) | Outcome                | 1 (10.30%)           |                                                              |
|              | Regimen convenience (Fosamprenavir/Fosamprenavir/ritonavir, Efavirenz, Atazanavir, Nevirapine/Lopinavir/ritonavir) | Outcome                | 2 (8.70%)            |                                                              |
| Opuni        | Monthly ART price (12$, 99$, 149$, 199$, or 298$)                                  | Structure              | 3 (23.50%)           | Clinic waiting times                                         |
|              | Clinic waiting times (30 min, 2 h, or 5 h)                                         | Structure              | 1 (33.20%)           |                                                              |
|              | HIV clinic branding (not branded as HIV clinic in any way, discretely branded as HIV clinic or clearly branded as HIV clinic) | Structure              | 4 (17.30%)           |                                                              |
|              | Clinic staff attitudes (kind, respectful, sympathetic, indifferent—neither kind nor rude or rude, disrespectful, unsympathetic) | Process                | 2 (26.00%)           |                                                              |
| Miller       | Adverse drug side effects                                                           | Outcome                | N/A                  | N/A                                                          |
|              | Pill burden                                                                        | Structure              |                      |                                                              |
|              | Medication inconvenience                                                            | Outcome                |                      |                                                              |
|              | Regimen potency                                                                    | Outcome                |                      |                                                              |
| Mühlbacher   | Life expectancy (maximal or moderate increase)                                      | Outcome                | 4 (10.02%)           | Emotional quality of life                                    |
|              | Long term side effects: improbable (<20% of patients) or possible (≥20% of patients) | Outcome                | 6 (5.56%)            |                                                              |
|              | Flexibility of dosing: max. 3 tablets/day or ≥4 tablets/day                          | Structure              | 5 (6.19%)            |                                                              |
|              | Physical quality of life: diarrhea or nausea less frequent or diarrhea or nausea more frequent | Outcome                | 2 (21.97%)           |                                                              |
|              | Emotional quality of life: disease not obvious for others or disease obvious for others | Outcome                | 1 (40.71%)           |                                                              |
|              | Social quality of life: participation in social life possible or participation in social life restricted | Outcome                | 3 (15.55%)           |                                                              |
| Beusterienb | Medication resistance                                                              | Outcome                | N/A                  | N/A                                                          |
|              | Lipodystrophy                                                                      | Outcome                |                      |                                                              |
|              | Regimen convenience                                                                | Outcome                |                      |                                                              |
|              | Moderate to severe rash                                                             | Outcome                |                      |                                                              |
|              | Moderate to severe nausea                                                           | Outcome                |                      |                                                              |
|              | Moderate to severe jaundice                                                         | Outcome                |                      |                                                              |
|              | Moderate to severe sleep disturbances                                               | Outcome                |                      |                                                              |
|              | Drug failure                                                                        | Outcome                |                      |                                                              |
|              | Moderate to severe vomiting                                                         | Outcome                |                      |                                                              |
|              | Cholesterol elevation                                                               | Outcome                |                      |                                                              |
|              | Moderate to severe jaundice                                                         | Outcome                |                      |                                                              |
|              | Moderate to severe depression                                                       | Outcome                |                      |                                                              |
|              | Moderate to severe dizziness                                                       | Outcome                |                      |                                                              |
Table 4 (continued)

| Authors | Attributes (levels)                                                                 | Dimension of attribute | Attribute importance | Most important attribute |
|---------|-----------------------------------------------------------------------------------|------------------------|----------------------|--------------------------|
| Lloyd   | Treatment benefit: 85%, 75%, or 65% chance undetectable viral load at 1 year        | Outcome               | N/A                  | N/A                      |
|         | Risk of rash: Treatment has a 1%, 5%, or 10% risk of rash during the first year     | Outcome               |                      |                          |
|         | Risk of kidney stones: In the next five years 0, 10 per 1000, or 37 per 1000 patients will develop kidney stones as a result of this treatment | Outcome               |                      |                          |
|         | Risk of jaundice: Treatment has a 1%, 5%, or 10% risk of jaundice during the first year | Outcome               |                      |                          |
|         | Risk of diarrhea: Treatment has a 5%, 10%, or 17% risk of diarrhea during the first year | Outcome               |                      |                          |
|         | Risk of psychological effects: Treatment has a 10%, 25%, or 50% risk during the first year | Outcome               |                      |                          |
|         | Risk of heart attack: In the next ten years, 0, 6 per 1000, or 40 per 1000 patients will suffer a heart attack as a result of this treatment | Outcome               |                      |                          |
|         | Long term safety profile: Product safety has been established over 10, 5, or 3 years | Outcome               |                      |                          |
| Rabkin  | Location of service delivery: Health facility/clinic close to home or workplace (10 min travel), Health facility/clinic further from home or workplace (45 min travel), Community-based DART services, or At home | Structure             | 3 (OR:1.70)          | Provider attitude        |
|         | Participants/others seen at the same visit: Individual or Group                    | Process               | 4 (OR:1.30)          |                          |
|         | Type of service provider: Professional health worker who is respectful and understanding, Professional health worker who is not respectful and understanding, Peer/layperson who is respectful and understanding, or Peer/layperson who is not respectful and understanding | Process               | 1 (OR: 2.40)         |                          |
|         | Times (days and hours) of operation: Workweek only (standard hours: 8 am–4 pm), Workweek with early morning hours (opens at 5 am), Workweek with evening hours (open until 8 pm), or Workweek + weekend hours (7 days a week, 8 am–4 pm) | Structure             | 7 (OR:1.00)          |                          |
|         | Frequency of routine visits for ART refill: Four times a year (every 3 months) or Two times a year (every 6 months) | Structure             | 5 (OR:1.09)          |                          |
|         | Total time for a visit, including registration, wait times, and time with providers. It does not include transportation time (30 min, 1 h, 2 h, or 4 h) | Structure             | 6 (OR:1.05)          |                          |
|         | The total cost of the visit including transportation, direct medical costs (e.g., consultation or booking fee, lab costs if not available at a public facility, non-ARV drug costs), costs of childcare: Free, $1, $3, or $10 | Structure             | 2 (OR:2.36)          |                          |
| Strauss | Location of service delivery: Health facility/clinic close to home or workplace (10 min travel), Health facility/clinic further from home or workplace (45 min travel), Community-based DART services, or At home | Structure             | 4 (OR:1.54)          | Provider attitude        |
|         | Participants/others seen at the same visit: Individual or Group                    | Process               | 7 (OR: 0.60)         |                          |
|         | Type of service provider: Professional health worker who is respectful and understanding, Professional health worker who is not respectful and understanding, Peer/layperson who is respectful and understanding, or Peer/layperson who is not respectful and understanding | Process               | 1 (OR:4.68)          |                          |
|         | Times (days and hours) of operation: Workweek only (standard hours: 8 am–4 pm), Workweek with early morning hours (opens at 5 am), Workweek with evening hours (open until 8 pm), or Workweek + weekend hours (7 days a week, 8 am–4 pm) | Structure             | 6 (OR:1.10)          |                          |
|         | Frequency of routine visits for ART refill: Four times a year (every 3 months) or Two times a year (every 6 months) | Structure             | 5 (OR:1.207)         |                          |
|         | Total time for a visit, including registration, wait times, and time with providers. It does not include transportation time (30 min, 1 h, 2 h, or 4 h) | Structure             | 3 (OR:1.70)          |                          |
|         | The total cost of the visit including transportation, direct medical costs (e.g., consultation or booking fee, lab costs if not available at a public facility, non-ARV drug costs), costs of childcare: Free, $1, $3, or $10 | Structure             | 2 (OR:1.77)          |                          |
| Authors | Attributes (levels) | Dimension of attribute | Attribute importance | Most important attribute |
|---------|--------------------|------------------------|---------------------|-------------------------|
| Yelverton | ART administration characteristics | Structure | N/A | |
| | Side effects | | | |
| | Long-term effects | Outcome | | |
| Sherer | Lowering viral load | Outcome | 1 (95%) | Lowering viral load |
| | Raising CD4 | Outcome | 2 (94%) | |
| | Durability | Outcome | 2 (94%) | |
| | Pill burden | Structure | 7 (70%) | |
| | Dosing frequency | Structure | 6 (74%) | |
| | Resistance profile | Outcome | 3 (89%) | |
| | GI SE | Outcome | 5 (79%) | |
| | Appearance SE | Outcome | 4 (80%) | |
| | Cholesterol SE | Outcome | 8 (60%) | |
| Fuster | Dosage | Structure | 4 (Mean: 8.41) | Efficacy |
| | Characteristics related to simplifications | Structure | 8 (Mean: 6.40) | |
| | Diet requirements | Structure | 7 (Mean: 7.16%) | |
| | Tolerance | Outcome | 5 (Mean: 8.18) | |
| | Toxicity | Outcome | 2 (Mean: 8.70) | |
| | Interactions | Outcome | 6 (Mean: 8.13) | |
| | Efficacy | Outcome | 1 (Mean: 9.55) | |
| | Available clinical evidence or information | Structure | 3 (Mean: 8.64) | |
| Ostermann | Dosing: Number of pills: one pill once daily, two pills once daily, three pills once daily, one pill twice daily | Structure | 3 (17.00%) | Side effect |
| | Administration: The pills are small, but you must take them with a meal of at least 400 kcal. The pills are large (about 1 inch), but you can take them with or without a meal; or The pills are small, and you can take them with or without a meal | Structure | 4 (8.00%) | |
| | Side effects: Moderate diarrhea, -Moderate sleeping problems,-Moderate headaches, Moderate dizziness, Moderate depression or Jaundice | Outcome | 1 (44.00%) | |
| | Long-term effects (over five years): Risk of heart attack, Risk of fracture owing to weakened bones, Risk of new or worse kidney problems, Risk of high cholesterol, or risk of high blood sugar | Outcome | 2 (32.00%) | |
| Sijstermans | Effect on life expectancy: Large positive effects(Live many years more), Moderate positive effects(Live a few more years), or Mild positive effects: Live a short while more (a few months, less than two years) | Outcome | 2 (23.00%) | Effect on physical activity |
| | Effect on physical activity: All physical activities without difficulty, Some physical activities with difficulty, or All physical activities with difficulty | Outcome | 1 (25.00%) | |
| | Risk of moderate side-effects: 1%(Low risk of side-effects), 2.5%(Medium risk of side-effects), or 5%(Higher risk of side-effects) | Outcome | 4 (17.30%) | |
| | Accessibility to the clinic: Less than 2 h, Between 2 and 5 h, or More than 5 h | Structure | 3 (20.50%) | |
| | Economic costs to access controls: Subsidized travel costs, Low travel costs, paid by the patient or High travel costs, paid by the patient | Structure | 5 (14.20%) | |
| Goossens | Effect on life expectancy: Large positive effects(Live many years more), Moderate positive effects(Live a few more years), or Mild positive effects: Live a short while more (a few months, less than two years) | Outcome | 2 (26.00%) | Effect on physical activity |
| | Effect on physical activity: All physical activities without difficulty, Some physical activities with difficulty, or All physical activities with difficulty | Outcome | 1 (27.50%) | |
| | Risk of moderate side-effects: 1%(Low risk of side-effects), 2.5%(Medium risk of side-effects), or 5%(Higher risk of side-effects) | Outcome | 4 (16.70%) | |
| | Accessibility to the clinic: Less than 2 h, Between 2 and 5 h, or More than 5 h | Structure | 3 (22.10%) | |
| | Economic costs to access controls: Subsidized travel costs, Low travel costs, paid by the patient or High travel costs, paid by the patient | Structure | 5 (7.60%) | |
identification, bulkiness, and the rattling noise produced by ART pill bottles.

### Table 4 (continued)

| Authors  | Attributes (levels)                                                                 | Dimension of attribute | Attribute importance | Most important attribute               |
|----------|-------------------------------------------------------------------------------------|------------------------|----------------------|----------------------------------------|
| Eshun    | Location of ART pick-up: Clinic or Community                                        | Structure              | 4 (7.70%)            | Frequency of ART pick-up               |
|          | Frequency of ART pick-up: Every month or Every 3 months                            | Structure              | 1 (62.14%)           |                                        |
|          | Time spent in picking up ART: 1 h total, 3 h total, or 6 h total                    | Structure              | 3 (10.30%)           |                                        |
|          | Time spent in seeing the doctor: 1 h total, 3 h total, or 5 h total                 | Structure              | 5 (1.10%)            |                                        |
|          | Adherence counseling: Individual counseling, Small group counseling (< 6 people), or Large group counseling (> 15 people) | Process                | 6 (0.65%)            |                                        |
| Hendricks| The drug has very high efficacy                                                     | Outcome                | 1 (RIS: 10.1)        | The drug has very high efficacy        |
|          | Maximum prolongation of life expectancy                                             | Outcome                | 2 (RIS: 9.7)         |                                        |
|          | Long duration of efficacy                                                          | Outcome                | 3 (RIS: 7.4)         |                                        |
|          | The drug improves the physical state                                               | Outcome                | 4 (RIS: 6.0)         |                                        |
|          | The drug does not generate resistance                                               | Outcome                | 5 (RIS: 5.4)         |                                        |
|          | Emotional and mental state improved                                                | Outcome                | 6 (RIS: 5.3)         |                                        |
|          | The dosing of the drug may vary                                                    | Structure              | 7 (RIS: 4.9)         |                                        |
|          | Once-daily application                                                              | Structure              | 8 (RIS: 4.5)         |                                        |
|          | The drug allows further therapy options                                             | Outcome                | 9 (RIS: 4.4)         |                                        |
|          | The drug can be taken along without problems                                         | Outcome                | 10 (RIS: 3.9)        |                                        |
|          | The drug does not affect the appearance                                             | Outcome                | 11 (RIS: 3.7)        |                                        |
|          | Long-term use of the drug is possible                                               | Outcome                | 12 (RIS: 3.5)        |                                        |
|          | It can also be used in case of comorbidities                                        | Outcome                | 13 (RIS: 3.4)        |                                        |
|          | Pregnancy allowed                                                                  | Outcome                | 14 (RIS: 3.2)        |                                        |
|          | Simple application: only a few tablets                                              | Structure              | 15 (RIS: 3.1)        |                                        |
|          | Long-term (hidden) side effects are unlikely                                        | Outcome                | 16 (RIS: 2.9)        |                                        |
|          | The drug does not cause additional costs                                            | Outcome                | 17 (RIS: 2.6)        |                                        |
|          | The drug allows an improved mobility                                                | Outcome                | 17 (RIS: 2.6)        |                                        |
|          | Flexible application                                                                | Structure              | 19 (RIS: 2.2)        |                                        |
|          | Social contact opportunities improved                                               | Outcome                | 20 (RIS: 2.0)        |                                        |
|          | Treatment does not require much time                                                | Structure              | 20 (RIS: 2.0)        |                                        |
|          | Self-application of the drug is possible                                            | Structure              | 22 (RIS: 1.8)        |                                        |
|          | Therapy-free intervals possible                                                     | Outcome                | 22 (RIS: 1.8)        |                                        |
|          | Inconspicuous drug intake                                                           | Outcome                | 24 (RIS: 1.7)        |                                        |
|          | Rarely occurring diarrhea                                                           | Outcome                | 25 (RIS: 1.2)        |                                        |
|          | Rarely occurring nausea                                                             | Outcome                | 26 (RIS: 0.9)        |                                        |
| Hauber   | The chance that medicine does not work. 7%, 15%, or 21%                             | Outcome                | 5                    | Chance of bone damage                  |
|          | Chance of having an allergic reaction: None, 1%, 3%, or 12%                         | Outcome                | 4                    |                                        |
|          | Chance of bone damage: None, 1%, 5%, or 10%                                        | Outcome                | 1                    |                                        |
|          | Chance of kidney damage: None, 1%, 5%, or 10%                                      | Outcome                | 2                    |                                        |
|          | What happens if you have bone damage or kidney damage: You don't know if the problem can be treated successfully, or The problem cannot be treated successfully | Outcome                | 3                    |                                        |
| Moyle    | Side effects                                                                        | Outcome                | 1 (RIS: 4.1)         | Side effects                           |
|          | Potency                                                                             | Outcome                | 2 (RIS: 4.0)         |                                        |
|          | Dosing frequency                                                                    | Structure              | 3 (RIS: 2.6)         |                                        |
|          | Total daily pill load                                                               | Structure              | 4 (RIS: 2.4)         |                                        |
|          | Number of pills per dose                                                             | Structure              | 5 (RIS: 2.1)         |                                        |

RIS: relative importance score; RI: relative importance; OR: odds ratio

### Process aspect of antiretroviral therapy
**Provider’s attitude** Two studies examined the providers’ attitude towards PLHIV while delivering care.
Participants needed a nice approach and respectful care and maintained confidentiality, and being requested to bring a family member of their own choice [37, 39].

Participants/others seen at the same visit One study evaluated the preference for individualized versus group-based ART models. Participants preferred individualized ART models to group-based models due to privacy concerns [37].

Patient involvement, relationships with providers, and shared decision making One study examined the preference for patient involvement, relationships with their providers, and practice for shared decision making. Participants preferred good relationships and open communication with their providers [49].

**Outcome aspect of antiretroviral therapy**

**Efficacy** Three studies evaluated the efficacy of ARVs [42, 45, 49]. Participants needed their medication to control the HIV virus.

**Side and or long-term effects** One study examined both the side effects and long-term effects of taking the ART drugs [49]. Participants were concerned with the side effects of drugs. They preferred drugs with reduced or no side effects. They were willing to accept and or pay for reduced side effects [49]. Patients were also concerned with long-term effects and willing to accept and or pay for reduced long-term health effects [49].

**Drug–drug interaction** Two studies evaluated the participants’ preference towards drug–drug interaction between ARVs or ARVs with other medications. Participants have a strong concern about drug–drug interactions [42, 49].

Besides, the attributes of inconvenience and novel ART delivery methods were clustered into structure and outcome dimensions of ART service delivery.

**Inconvenience** Two studies asked the participants’ preference regarding convenience while taking medications. Participants mentioned their concern about inconvenience related to social life, food requirement, time in taking drugs, and child care activity [45, 49].

**Novel ART delivery methods** One study highlighted the importance of novel ART delivery approaches. Participants needed novel delivery of ART services, including coformulation of ART with chronic diseases drugs and injectable drug options [42].

**Integration of quantitative evidence and qualitative evidence**
The findings from individual quantitative and qualitative syntheses complement each other. Regarding the classification of attributes, the outcome aspect of ART took two-third of the share in the quantitative synthesis, whereas the structure aspect of ART took half of the share in the qualitative synthesis. The qualitative evidence explained well why the patients prefer or did not prefer a certain aspect of antiretroviral therapy service provision across the included quantitative studies. Attributes such as HIV clinic branding, accessibility to the clinic, time spent in seeing the doctor, and buddy system from the quantitative evidence were not explored in the qualitative studies and could therefore be investigated in future qualitative studies. On the other hand, the source of information on ART, packaging of ART and self-repackaging, and patient involvement, relationships with providers, and shared decision-making themes of the qualitative evidence were not tested in the quantitative studies. These factors would have implications for future discrete choice experiments. Figure 2 summarizes the attributes derived from both qualitative and quantitative evidence using a Donabedian framework.

**Discussion**

Overall, this systematic mixed studies review identified several attributes underlying antiretroviral therapy choice in PLHIV. The conceptual attributes used by previous studies were clustered into the structure, process, and outcome domains of ART service delivery. The type of attribute and its relative importance on patients' preferences varied across the included studies, which may have several reasons, such as the method of analysis, the selection procedure of the attributes and their levels, and/or the specific research question of the study.

**Structure attributes**

In this review, health facility-based models of ART were highly valued than community-based models. It is consistent with previous evidence [16, 56]. This type of valuation could continue overstretching the existing health system and might create a barrier in scaling up ART to where PLHIV live and work hence deter achievement of 95-95-95 targets by 2030. Respondents’ choice of service provider type was influenced by the providers’ characteristics which are in line with previous evidence [57]. Healthcare workers were more preferred for their knowledge of drugs and disease, whereas trained PLHIV and foreigners (outside of their community) were preferred for their breaking down barriers and maintaining confidentiality. This highlights a difference in patient priority and has implications for patient-centered care. Regarding the source of information for ART, the majority of the participants in this review received information from health care providers, whereas some of them got information from TV and Radio. This finding is in line with a previous nationwide study where the majority of the
participants ranked doctors in their top three information sources, HIV positive counselors and magazines next, and brochures and newsletters as last [58].

An increased total cost of visits (transportation, direct medical costs, and costs of childcare) was negatively associated with respondents’ choice of ART service, which is comparable with the previous systematic review [59]. This has implications for access to service and insurance coverage and further progress towards universal health coverage. Furthermore, less frequent clinic visit was highly preferred by respondents and is comparable with earlier reviews [16, 60]. The WHO’s differentiated service delivery initiative has also recognized the positive impacts of appointment spacing ART delivery models on patient and health system efficiencies [10]. Similarly, shorter travel distance was found to be preferred by participants, which is comparable with the previous review [16]. This has implications for access to service and demand for increased investment in community-based ART distribution models.

Regarding the waiting time to access antiretroviral drugs and clinical consultations, participants had more value on reduced waiting time, as similarly reported in previous reviews [14, 16]. This has implications for patient satisfaction. Similarly, respondents chose flexible or convenient clinic hours, including extra hours and weekends, which is consistent with an earlier systematic review [14]. This has policy implications on the health workforce and other resource allocation to increase service availability beyond the standard routine practice hours and days. Furthermore, participants preferred the availability of a buddy system (others take the drug in case of severe illness). From a policy perspective, this suggests that involving family members in care to maintain continuity of care as needed might improve patient drug adherence hence good treatment outcomes. HIV clinic branding was negatively associated with patient preference for ART service provision. This has implications for stigma reduction and care optimization since clinic branding might be a barrier to ART service utilization and adherence.

Reduction in pill burden was valued highly by patients. However, this would not continue as a concern since the current medication is based on fixed-dose single-tablet combinations. Besides, a smaller pill size was preferred by respondents. This implies for future patient-centered pharmaceutical drug formulation to ease medication swallowing. Patients also preferred injectable or liquid forms of drugs to reduce pill burden, avoid swallowing pills and unpleasant taste or reduce intake frequency. This has implications for drug innovators to bring new ARV options. In this review, patients had less preference on current ART packaging due to privacy issues and prioritized practicing self-repackaging. However, this could have a negative effect on the patient outcomes as a previous study reported an association of patient-initiated repackaging of ART with virological failure and ART drug resistance [61]. A patient-friendly pharmaceutical pack design is needed in future drug development investments, as inferred from this review.

Process attributes
Good providers’ attitude was found positively associated with patients’ choice for ART service. This is consistent with the previous reviews [14, 16]. This has important implications for bringing interventions to continue enhancing providers’ empathy and positivity. Similarly, patients valued more their involvement and making a shared decision in HIV treatment and having good relationships with their providers, which is in line with the WHO’s people-centered health care policy framework [62] and a previous review [14]. This inferred that the shared decision model is appropriate in complex ART decisions. In this review, PLHIV were willing to accept individualized models than group-based models to reduce HIV stigma and discrimination even though group-based models were initially designed for reducing patients’ waiting time while receiving care. It is in line with a systematic review undertaken in sub-Saharan Africa [59]. This highlights much effort is needed to scale up group-based ART initiatives to enhance better patient outcomes.

Outcome attributes
In this systematic review, patients highly valued effective ARV drugs, which is in line with a previous systematic review [63]. Also, the long duration of the drugs was highly valued. Likewise, increased quality and quantity of life were valued more considered as the important attributes underlying HIV drugs. Beyond the potency, increased life expectancy, and quality of life benefits of ARVs, patients also preferred the drugs to be with no or reduced side effects, long-term health problems, and drug–drug interactions. This is in agreement with the previous systematic review [63]. The WHO’s consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection [5] also acknowledged the above-mentioned attributes of HIV medications. This has implications for accommodating patient preferences in future drug discovery and development efforts by balancing the benefits and harms of treatment options.

Besides, this review found that novel ART delivery methods and inconvenience while taking medications as the relevant attributes affecting the preference of PLHIV on ART service delivery. A study conducted in the United
| Initial concepts | Emergent themes | Supporting quotes and contributing studies | Final themes | Dimension of final themes |
|------------------|-----------------|------------------------------------------|--------------|-------------------------|
| Receiving ART information from TV and Radio | Media source | “I got the information on ART from the TV and radio. They said there is a drug that can help AIDS patients to live longer.” [39] | Source of information on ART | Structure |
| Hearing about ART information from the hospital | Health care providers at the hospital | “At the hospital, I heard about it from the hospital. After testing when I was positive, the nurse informed me of the availability of ART.” [39] | | |
| Being told by a Nurse about the availability of ART | | “I heard of the ART drug from the hospital when my husband brought me, and I was tested positive. The doctor said there is a drug that will make us stronger all the time.” [39] | | |
| Being informed by the doctor about the availability of a drug | | | | |
| Hospital education and preparation | Health facility service features | “For ART drugs we prefer the hospitals because these drugs are not just any drugs to be administered at home, because there is a lot of education and preparation before these drugs are given.” [39] | Preferred place for ART services | Structure |
| Meet and interact with colleagues | | “We prefer facility-based because it will be a big problem if it is home-based. Anytime I come here, people see me coming to the hospital for a different purpose other than coming for the ART drug, and it is better that way. But if it is home-based, it will make us think about it, and that alone can kill us early.” [39] | | |
| An opportunity for discussion with providers | | “I prefer facility-based like the ***** hospital because when we all come to meet at the center to take our drug, we share our problems together and laugh and make ourselves happy which help take some of our sorrows away.” [39] | | |
| Avoids stigma and discrimination | | “I prefer the facility-based service to home-based because there are some people who have the disease but don’t want their relations to know because of stigmatization. Home-based treatment will increase stigmatization.” [39] | | |
| Open location of some ART clinics deter ART access | | “...getting treated at the clinic is important...because there are times when you will be at the clinic you can discuss until you are satisfied... than at home or at shops where you can just go and pick your pills there is no time for discussions.” [37] | | |
| Drugs can’t be delivered at home | Home-based service features | “...Everyone goes to the clinic, so no one will know why you are coming here [to the clinic], you may say you have a headache... Home delivery is a no...” [37] | | |
| Home-based treatment will increase stigmatization | | “I don’t like them [medications] to be brought home because my neighbors may know, and I may lose hope. I will lose hope forever.” [37] | | |
| Home-based service may demand training more ART provider | | “...getting treated at the clinic is important...because there are times when you will be at the clinic you can discuss until you are satisfied... than at home or at shops where you can just go and pick your pills there is no time for discussions.” [37] | | |
| Health workers know how drug improves patient context | Health worker | “I will prefer health workers who have been rendering the service because they know how the drug has been improving our situation.” [39] | Preferred person to deliver ART services | Structure |
| Doctors and nurses know about drugs and disease due to their training and experience | | “We want the doctors and nurses because they have been trained, so they know all about the drugs and the disease.” [39] | | |
| PLHIVs should be trained to help in giving out the drugs | Trained PLHIV | “PLHIVs should be trained to help in giving out the drugs. If this is done, it will encourage us to feel free to go for the drugs because if a PLHIV gets there and sees the colleague HIV patient giving the drug they will not feel shy again.” [39] | | |
| Trained PLHIV encourages the patient to feel free to go for drugs | | “I think it is best if foreigners come because the indigenes would let others know about your status. As of now, those who give the drug to us are not from this community, and they relate to us very well. I like the way they relate to us, so if they continue, it will be better.” [39] | | |
| Trained PLHIV avoids patients’ feeling shy | | | | |
| Choosing foreigners since indigenes might break confidentiality | Foreigners | | | |
| Foreigners relate with patients well | | | | |
Table 5 (continued)

| Initial concepts | Emergent themes | Supporting quotes and contributing studies | Final themes | Dimension of final themes |
|------------------|-----------------|-------------------------------------------|--------------|--------------------------|
| Nice and respectful Provider’s attitude | *The health workers behave towards us very well. They handle us like we are siblings. In the beginning, before they put you on these drugs, they ask you to bring a family member along. It is not difficult to get such a person. It should be someone whom you believe will not go and spread the information that you are infected. When they put you on the drugs, you wouldn’t have to come with anybody to the hospital again.* [39] | Provider’s attitude | Process |
| The provider doesn’t request a family member when putting on ART | *They are generally good. She will ask which part of your system is disturbing you. They don’t meet us with frown faces; we converse with them nicely.* [39] | | |
| Nice and sympathetic Respect and confidentiality | *We expect that when we come here for a service that we are treated like normal people in the same way that someone with flu or a headache is treated and not to be labeled as ‘the ones who have come for medication’.* [37] | | |
| Unable to afford the cost of transport Transportation cost | *The distances are far. Due to this, there are some people who hardly come for the drugs on a regular basis because they cannot afford the cost of transport involved.* [39] | Cost of ART medications | Structure |
| Out-of-pocket cost Drug cost | *My problem is transportation. Where I stay is far from where I take the drugs. It cost me about GHC5 anytime I come for my drugs. Under such circumstances, if you don’t have somebody to support you financially, it will be difficult for you to collect your drugs regularly as required.* [39] | | |
| High insurance co-payment | *The drugs should be given to us free of charge. Sometimes, for one year, I will not have money, but they give the drugs to me.* [39] | | |
| The patient recommends a free drug cost | *My major concern is that I will not be able to get access, or to get it for free more, because of the change of the government.* [42] | | |
| Patient willing to pay whatever amount required as a drug is available | *Some people, I mean, it’s affordable. Then you have to come to where the insurance will pay so much, and then you have co-payment. And that’s still expensive for some people.* [42] | | |
| | *If I need to go back to Mexico, how will I get it?* [42] | | |
| | *If I had to pay for the medicine myself, I’d probably be dead. […] Because I couldn’t afford it.* [49] | | |
| Long waiting time Waiting time | *At times, you spend a lot of time over there, from 8.00 am to 3.00 pm, due to huge numbers coupled with a small number of health workers.* [37, 39] | Time spent at clinics in ART pick up | Structure |
| Shorter waiting time | *It depends on your schedule for collecting the ART drugs; yesterday, for instance, by 1:30 pm, everybody had been served, and the center had closed. There are some days when the pressure is quite high, particularly on Fridays but on Wednesdays, there are few people.* [39] | Times (hours and days) of operation | Structure |
| Flexible clinic hours Times of operation | | | |
| Day of schedule | | | |
| Less frequent visit/appointment Visit frequency | Not applicable [37] | Visit frequency | Structure |
| Once or twice a year visit with larger supplies of ART dispensed at each visit | | | |
| People want to be seen individually Individual model preference | *I think people want privacy in general. No one wants their health status to be known, so people want to be seen individually, and I think there is no one who put a sticker there.* [37] | Individual model preference | Process |
| The patient wants to come alone but do not mind coming with a family member | *People are a problem. I want to come alone, but I do not mind coming with a family member so that they know where I get my medication just in case I get sick.* [37] | | |
| Initial concepts | Emergent themes | Supporting quotes and contributing studies | Final themes | Dimension of final themes |
|------------------|-----------------|---------------------------------------------|--------------|---------------------------|
| Good relationship and open communication Patient as a final decision maker The patient decides based on the doctor’s recommendation Paternalism | Good relationship and open communication Shared decision making | “I am not my diagnosis. I am somebody. [...] So I think he is starting to understand that, that I need more than ‘your levels are fine.’ He literally turns the screen and scrolls down and shows me the levels and recent tests and what he wants and what he thinks how we should move forward.” [49] “You know, I would talk to my doctor, what’s his experience with the medication and what he knows about the medication [...]. I would pump my doctor for information, what he knows [...], how an adverse reaction relates to the majority of people on this medication as opposed to a small group.” [49] “And fortunately that I have excellent communication with my doctor because if I have an issue with home or something comes up, I can email him, and I will hear back from him immediately. So that helps a lot to have good communication.” [49] “Ultimately, it is that patient’s decision, but I take the advice of what my doctor offers.” [49] “Like I said, I did it because the doctor prescribed them for me. [...] And I figured she would know what was best for me. She’s the doctor, and I’m not. [...] So whatever she prescribed, I took. [...] Just as simple as that, you know.” [49] | Patient involvement, relationships with providers, and shared decision making | Process |
| Single tablet daily The problem of swallowing big pills Willingness to accept higher pill burden in exchange for reduced side or long-term effect | Concerns of pill burden | “One a day. That’s a lovely thing to have to do.” [49] “One of the main things I would require is for that medicine to also be like one tablet a day, but the amount of that new med is not as important as what it brings; you know, what it has to offer.” [49] [Interviewer:] “Let’s assume [...] you would go to a regimen which means twenty-seven tablets, but there would be not such a high risk for having liver problems, and your renal system would be great, would you do it?” [Subject:] “I would try it, yes.” [49] [Interviewer:] “So there’s a drug which would cause dizziness, but you could go down to one tablet in the morning, and there’s a drug which doesn’t cause dizziness, but you would have to take two tablets two times daily.” [Subject:] “Two tablets two times a day. I probably would go with the two tablets twice a day.” [49] | Pill burden and pill size | Structure |
| The patient prefers drugs in the form of a liquid, capsule, or injection to either avoid swallowing pills or to lower the intake frequency with an injection once a week or month Feeling burdened due to daily drug taking Unpleasant drug taste | Drug administration choice | “The other thing is I would like for or want this medicine to be in a convenient 3, 6, or 12-months injections.” [42] “One 37-year-old female participant raised the possibility of monthly ART injections, stating this would allow them to receive their medication at the clinic and eliminate the risk of unwanted disclosures in their daily lives.” [35] “Some pills have an after taste once you swallow it, and it can be a severe case to the point where you just do not want to take it.” [49] | Drug administration | Structure |
| Initial concepts | Emergent themes | Supporting quotes and contributing studies | Final themes | Dimension of final themes |
|------------------|-----------------|------------------------------------------|--------------|--------------------------|
| Privacy of drugs | Perceived challenges with ART packaging and self-repackaging | “It is easy for people to recognize the ARTs when they are in their boxes. Even a child can recognize them.” [35] | ART packaging and self-repackaging | Structure |
| | | “If the medicines are in the bottle, it’s a normal thing to produce some kind of noise, and this is not for ARTs only; it’s for all other types of medicines.” [35] | | |
| | | “Some of us stigmatize ourselves, thinking that if people see us carrying the medicines in the box, they will know that we have HIV.” [35] | | |
| | | “If people see [the pills], they will not respect the person who takes the medicines because they will know your status.” [35] | | |
| | | “Maybe they are afraid to be stigmatized. You know people live in different circumstances, so it depends on the community that the person lives in and how they perceive the problem.” [35] | | |
| | | “There are some patients who don’t like to be seen by others; they hide even while at the clinic. They hide because they are afraid to be seen by the people they know, especially if it’s their first time.” [35] | | |
| | | “There are patients who are supposed to take two drugs in a day, morning and evening. So, if you repack, how are you going to remember which ones to take?” [35] | | |
| | | “If someone commits to taking the medicines as prescribed, it doesn’t matter how the medicines are packed” [35] | | |
| | | “There is not any relationship between the way the medicines are packed and taking them. If someone commits to taking the medicines as prescribed, it doesn’t matter how the medicines are packed” [35] | | |
| | | “I think they should remove the box because of its size. If they remove the box, the bottle will not be easily seen, especially for men who like to put the medicines in their trouser pockets.” [35] | | |
| | | “When I came here the first time, I saw other people removing the box, and I decided to do the same.” [35] | | |
| | | “I think the major reason is the size of the bottle. Sometimes when you walk the medicines will make noise, so you will be afraid because you haven’t accepted your HIV diagnosis.” [35] | | |
| | | “I would suggest the medicines be given in blister packs. Blister packs are transparent, but they are well packed. This will make them easy to carry, and patients will feel comfortable putting them in their bag because they do not make noise.” [35] | | |

| Perceived benefits of current ART packaging | | | | |
| Relationship between self-repackaging and perceptions of ART adherence | | | | |
| Recommendations for patient-centered ART packaging | | | | |
| Easily identifiable ART box | Bulky packaging | Plastic bags reduce noise | Perceived stigma | |
| Current packaging valuable | Health providers advise not repacked ART | Continued practice of repackaging | The connection between self-repackaging and poor adherence | |
| The link among stigma, repackaging, and adherence | The pillbox should be removed | | | |
| | Boxes should be small in size and non-descriptive | Learn self-repackaging from others | Inconvenient box discarding at home | |
| | Disliked pill bottle | Monthly ART injections | “Small pouch” Blister packs | |
Table 5 (continued)

| Initial concepts                                                                 | Emergent themes                                                                 | Supporting quotes and contributing studies                                                                 | Final themes   | Dimension of final themes |
|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|----------------|--------------------------|
| Regimen potency                                                                  | Medication controls HIV                                                          | “Want a regimen that was most effective at fighting HIV and prolonging life, regardless of side-effect severity, complexity, inconvenience, or pill burden” [45] | Efficacy       | Outcome                  |
|                                                                                  |                                                                                  | “Maintain the levels of HIV in control” and “to help me feel better … even on bad days” [42]                |                |                          |
|                                                                                  |                                                                                  | “Well, first, of course, would be the efficacy of the medication, what its track record is and everything” [49] |                |                          |
| Long term side effects (cardiovascular disease, osteoporosis, fat redistribution, raised cholesterol, liver damage, and kidney damage, brain effects) | Long term effects                                                                | “I wouldn’t want it to interfere with my organs, and that’s my concern about HIV meds or any long-term meds that I’m prescribed for an ongoing period of time [.] I would rather be on herbal drugs than to lose my kidneys and liver” [49] | Long-term effect | Outcome                  |
| Willingness to accept higher pill burden in exchange for reduced long-term effect |                                                                                  | “Let’s assume [.] you would go to a regimen which means twenty-seven tablets, but there would be not such a high risk for having liver problems, and your renal system would be great, would you do it?” [Subject] “I would try it, yes.” [49] |                |                          |
| Restricted outdoor activities                                                    | Concerns related to drug side effects                                            | “If [.] this is a medicine that I have to take for a better quality of health and it interrupts my sleep for any period of time, it wouldn’t be acceptable. I couldn’t tolerate it.” [49] | Side effect    | Outcome                  |
| Restricted physical activity                                                     |                                                                                  | “Dizziness is a problem. I worry about falling.” [49]                                                      |                |                          |
| Selection of place and time of medication due to fainting                        |                                                                                  | “You start to learn okay, if [.] I know that the diarrhea is going to hit 2 h after I take my medicines, then I’m going to prepare for it.” [49] |                |                          |
| Medication interfere with employed and non-employed work                         |                                                                                  | [Interviewer:] “So there’s a drug which would cause dizziness, but you could go down to one tablet in the morning, and there’s a drug which doesn’t cause dizziness, but you would have to take two tablets twice daily.” [Subject] “Two tablets two times a day. I probably would go with the two tablets twice a day.” [49] |                |                          |
| Stopped working due to side effects                                              |                                                                                  | [Interviewer:] “Let’s assume your drug actually results in sleeping problems. You go to your doctor [.] He says, well, you know, there’s something else, but co-pays are real expensive. We’ve got to have some co-pay, $100.00.” [Subject] “Yes” [Interviewer:] “$150.00?” [Subject] “Yes” [Interviewer:] “$200.00?” [Subject] “$250.00?” [Subject] “My stopping point would be 200.” [49] |                |                          |
| Drug interruption due to side effects                                            |                                                                                  | “One respondent, for example, reported being unable to take his scheduled dose because he was stuck in traffic and another reported that she had missed a dose because she had been unable to take a break from her job as a cashier” [45] |                |                          |
| Willingness to accept higher pill burden in exchange for reduced side effect     | The trade-off for reduced side effect                                           | “You’re supposed to take that with a meal [. But] I never eat dinner at the same time. It’s just, it’s kind of an inconvenience.” [49] |                |                          |
| Willingness to pay for reduced side effects                                      |                                                                                  | “Many noted taking medications with more complex regimens were problematic when they had to take medications with meals.” [45] |                |                          |
| Skip doses while in the town, drink, or take illicit drugs                       | Social life inconvenience                                                        | “One subject reported that she had stopped taking her medications because she felt so nauseous and weak that she was unable to care for her newborn baby (she subsequently switched to a regimen with milder side-effects).” [45] | Inconvenience   | Structure and outcome    |
| Drug interference with family and social life                                     |                                                                                  | “One subject reported that she had stopped taking her medications because she felt so nauseous and weak that she was unable to care for her newborn baby (she subsequently switched to a regimen with milder side-effects).” [45] |                |                          |
| Skipping doses due to important engagements                                       | Food inconvenience                                                               | “One subject reported that she had stopped taking her medications because she felt so nauseous and weak that she was unable to care for her newborn baby (she subsequently switched to a regimen with milder side-effects).” [45] |                |                          |
| Food requirement                                                                 | Time inconvenience                                                              | “One said he felt embarrased to take his medications in front of his kids and their friends.” [45]        |                |                          |
| Missing drug due to inconvenient time                                            |                                                                                  | “One said he felt embarrased to take his medications in front of his kids and their friends.” [45]        |                |                          |
| Drug stopping due to child care priority                                         |                                                                                  | “One said he felt embarrased to take his medications in front of his kids and their friends.” [45]        |                |                          |
| Forget to take the drug due to child-caring                                      |                                                                                  | “One said he felt embarrased to take his medications in front of his kids and their friends.” [45]        |                |                          |
| Initial concepts                                      | Emergent themes                     | Supporting quotes and contributing studies                                                                                                                                                                                                 | Final themes                  | Dimension of final themes |
|------------------------------------------------------|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|---------------------------|
| Drug–drug interaction                                 | Pharmacologic concern               | “My major concern is the interaction between other medicines because I have other conditions. I take other medicines. And they’re very strong, and I think that in the long-run, I can have a lot of complications.” [42]  
“Participants reported drug interactions in their medical history and highlighted the importance to not only check for interactions with HIV medicines, but also for medicines for comorbidities.” [49] | Drug interaction            | Outcome                   |
| Coformulation of ART with chronic disease drugs      | ARVs also treating other chronic conditions | “Several patients expressed a desire to co-formulate their ART with medication for another chronic illness like high blood pressure: I am wondering since high blood pressure is prevalent in the African American community, if they can have an antihypertensive medication that also helps with high blood pressure.” [42]  
“The other thing is I would like for or want this medicine to be in a convenient 3, 6, or 12-months injections.” [42] | Novel ART delivery approach | Structure and outcome     |
| Hypertension controlling ART drug                     | Injectable drugs reduce the frequency of visit |                                                                                                                                                                                                                                                                                    |                              |                           |
| Patients want injectable drugs at 3, 6 or 12 months  |                                                                                             |                                                                                                                                                                                                                                                                                    |                              |                           |
States and Canada supports our review that patients preferred the long-acting injectable treatment regimen to avoid daily taking of drugs or reminders of having HIV [64]. Similarly, a systematic review found that HIV treatment fatigue occurred due to inconvenient scheduling, adverse side effects, and lifestyle changes which might affect patients’ choice of ART service delivery [65].

Strengths and limitations of the review
This mixed-methods systematic review incorporated studies using both qualitative and quantitative methodologies to get a comprehensive understanding of the aspects of ART service delivery considered important by PLHIV in previous studies. This has the advantage of generating more robust implications for practice, research, and policymaking. This review has two noticeable limitations. First, as with the limitations of any systematic review, there is the possibility of incomplete retrieval of identified research due to the scope of the search terms and the databases searched. Second, there might be a probability of selection bias as only published studies in the English language were included.

Conclusions
This review gives an overview of patients’ preferences for ART service provision features. Patients on ART had different values on the structure, process, and outcome components of antiretroviral therapy. The relative importance of each attribute used in the previous studies, as well as the patients’ preferences for ART service delivery characteristics, varied across the included studies. Thus, policymakers and practitioners should be aware of the aspects of ART that are considered as particularly important by the patients and the trade-offs, they are willing to make between various aspects of ART. Moreover, this review can be helpful for researchers planning to undertake a DCE in ART service since it gives a comprehensive picture of ART service delivery attributes and levels.

Abbreviations
AIDS: Acquired Immunodeficiency Syndrome; ART: Antiretroviral Therapy; ARV: Antiretroviral; DCE: Discrete choice experiment; HIV: Human Immunodeficiency Virus; PLHIV: People living with HIV; WHO: World Health Organization.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12962-021-00310-7.

Additional file 1. Search strategy for PubMed, Embase, Web of Science, and CINAHL databases.
Additional file 2. Data extraction tool.
Additional file 3. Mixed Methods Appraisal Tool (MMAT) checklist.

Acknowledgements
We acknowledge the authors of the articles included in this review.

Authors’ contributions
All authors developed the literature search strategy. YAB and FAT conducted the literature search. YAB and MY assessed the quality of the studies. YAB
and AA extracted the data. The manuscript was drafted by YAB and FAT. All authors read and approved the final manuscript.

**Funding**

No funding was received for this study.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article and its additional files.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Public Health, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia. 2. Department of Health Systems and Policy, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. 3. Department of Accounting, Finance, and Economics, Griffith University, Brisbane, Australia.

**Received:** 19 April 2021  **Accepted:** 16 August 2021  **Published online:** 30 August 2021

**References**

1. Joint United Nations Programme on HIV/AIDS. Global HIV & AIDS statistics — Fact sheet 2021. https://www.unaids.org/en/resources/fact-sheet. Accessed 13 Mar 2021.

2. World Health Organization. HIV/AIDS _Fact sheet 2020. https://www.who.int/news-room/fact-sheets/detail/hiv-aids. Accessed 31 July 2020.

3. Joint United Nations Programme on HIV/AIDS. AIDS and the sustainable development goals 2020. https://www.unaids.org/en/AIDS_SDGs. Accessed 15 June 2020.

4. Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS; 2014.

5. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016.

6. El-Sadr WM, Rabkin M, DeCock KM. Population health or individualized care in the global AIDS response: synergy or conflict? AIDS. 2016;30(14):2145.

7. The International AIDS Society (IAS). What is differentiated ART delivery? 2021 https://differentialservicedelivery.org/. Accessed 29 Jan 2021.

8. Duncombe C, Rosenblum S, Hellmann N, Holmes C, Wilkinson L, Biot M, et al. Reframing HIV care: putting people at the centre of antiretroviral delivery. Trop Med Int Health. 2015;20(4):430–47.

9. Grimsrud A, Bygrave H, Doherty M, Ehrenkranz P, Ellman T, Ferris R, et al. Reimagining HIV service delivery: the role of differentiated care from prevention to suppression. J Int AIDS Soc. 2016;19(1):21484.

10. International AIDS Society. Differentiated care for HIV: a decision framework for antiretroviral therapy delivery. Durban: International AIDS Society Durban; 2016.

11. World Health Organization. Key considerations for differentiated antiretroviral therapy delivery for specific populations: children, adolescents, pregnant and breastfeeding women and key populations. Geneva: World Health Organization; 2017. 2017. Contract No.: WHO/IV/2017.34.

12. Zanolini A, Sikombe K, Sikazwe J, Eshun-Wilson I, Somwe P, Moore CB, et al. Understanding preferences for HIV care and treatment in Zambia: evidence from a discrete choice experiment among patients who have been lost to follow-up. PLoS Med. 2018;15(8):e1002636.
patients on antiretroviral therapy in Zambia: a discrete choice experiment. J Acquir Immune Defic Syndr. 2019;81(5):540.

35. Muiruri C, Jazowski SA, Semvua SK, Karia FP, Knettell BA, Zullig LL, et al. Does antiretroviral therapy packaging matter? Perceptions and preferences of antiretroviral therapy packaging for people living with HIV in Northern Tanzania. Patient Prefer Adherence. 2020;14:153.

36. Opuni M, Bishi D, Gray GE, McIntyre JA, Martinson N. Preferences for characteristics of antiretroviral therapy provision in Johannesburg, South Africa: results of a conjoint analysis. AIDS Behav. 2010;14(4):807–15.

37. Rabkin M, Strauss M, Mantell JE, Mapingure M, Masvawure TB, Lamb MR, et al. Optimizing differentiated HIV treatment models in urban Zimbabwe: assessing patient preferences using a discrete choice experiment. AIDS Behav. 2020;24(1):1–17.

38. Tanle A, Akwasi-K-K, Marwah S, Kobina E-D, Asiedu SO, Lamptey J. Preferences for antiretroviral therapy services: qualitative evidence from people living with HIV in Ghana. J Geogr. 2017;9(1):1–16.

39. Zanolini A, Sikombe K, Sikazwe S, Eshun-Wilson I, Somwe P, Bolton Moore C, et al. Understanding preferences for HIV care and treatment in Zambia: Evidence from a discrete choice experiment among patients who have been lost to follow-up. PLoS Med. 2018;15(8):e1002636.

40. Hauber AB, Mohamed AF, Watson ME, Johnson FR, Hernandez JE, et al. Benefits, risk, and uncertainty: preferences of antiretroviral-naive African Americans for HIV treatments. AIDS Patient Care STDs. 2009;23(1):29–34.

41. Hendriks A, Wijnen B, van Engelen R, Conde R, Evers SM, Gonzalez J, et al. A best-worst scaling in Colombian patients to rank the characteristics of antiretroviral treatment. J Med Econ. 2018;21(5):468–73.

42. Miller LG, Huffman HB, Weidner BA, Hays RD. Patient preferences regarding antiretroviral therapy. Int J STD AIDS. 2002;13(9):593–601.

43. Ostermann J, Mühlbacher AC, Stoll M, Mahlich J, Nübling M. Patient preferences for HIV/AIDS therapy—a discrete choice experiment. Heal Econ Rev. 2013;3(1):1–8.

44. Beusterien KM, Dziekan K, Flood E, Harding G, Jordan J. Understanding patient preferences for HIV medications using adaptive conjoint analysis: feasibility assessment. Value Health. 2005;8(4):453–61.

45. Eaton EF, McDavid C, Banasiewicz MK, Mugavero MJ, Knight S. Patient preferences for antiretroviral therapy: effectiveness, quality of life, access and novel delivery methods. Patient Prefer Adherence. 2017;11:1585.

46. Hauber AB, Mohamed AF, Watson ME, Johnson FR, Hernandez JE. Effect of frequency of clinic visits and medication pick-up on antiretroviral treatment outcomes: a systematic literature review and meta-analysis. J Int AIDS Soc. 2017;20:21647.

47. Ramadhan HO, Muiruri C, Maro VP, Nyombi B, Omondi M, Mushy JB, et al. Patient-initiated repackaging of antiretroviral therapy, viral suppression and drug resistance. AIDS Behav. 2018;22(5):1671–8.

48. World Health Organization. People-centred health care: a policy framework 2007. https://www.who.int/publications/i/item/9789249061317? Accessed 24 Apr 2021.

49. de los Rios P, Okoli C, Young B, Allan B, Castellanos E, Brough G, et al. Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries. Popul Med. 2020;2:1–3.

50. Garris C, Heidenreich S, Arthurs E. Perceptions of and preferences for oral or long-acting injectable antiretroviral treatment regimens in the United States and Canada. 2019:2–6.

51. Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Med. 2015;20(3):255–65.